Matches in DBpedia 2015-04 for { <http://dbpedia.org/resource/Aflibercept> ?p ?o }
Showing triples 1 to 66 of
66
with 100 triples per page.
- Aflibercept abstract "Aflibercept (INN, USAN) is a biopharmaceutical drug invented by Regeneron Pharmaceuticals, approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zaltrap. As the active ingredient of Zaltrap, the substance is called ziv-aflibercept in the US.It is an inhibitor of vascular endothelial growth factor (VEGF).Aflibercept is being co-developed for cancer treatment by Sanofi and Regeneron under a deal signed in 2003, and is being co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006.".
- Aflibercept atcPrefix "L01".
- Aflibercept atcSuffix "XX44".
- Aflibercept casNumber "862111-32-8".
- Aflibercept fdaUniiCode "15C2VL427D".
- Aflibercept wikiPageID "17545444".
- Aflibercept wikiPageRevisionID "626396821".
- Aflibercept atcPrefix "L01".
- Aflibercept atcSuffix "XX44".
- Aflibercept c "4318".
- Aflibercept casNumber "862111".
- Aflibercept chemspiderid "NA".
- Aflibercept h "6788".
- Aflibercept hasPhotoCollection Aflibercept.
- Aflibercept kegg "D09574".
- Aflibercept legalUs "Rx-only".
- Aflibercept licenceUs "Aflibercept".
- Aflibercept molecularWeight "96.9".
- Aflibercept n "1164".
- Aflibercept o "1304".
- Aflibercept pregnancyUs "C".
- Aflibercept routesOfAdministration "Injection".
- Aflibercept s "32".
- Aflibercept tradename "Eylea, Zaltrap".
- Aflibercept unii "15".
- Aflibercept verifiedfields "changed".
- Aflibercept verifiedrevid "477243410".
- Aflibercept watchedfields "changed".
- Aflibercept subject Category:Angiogenesis_inhibitors.
- Aflibercept subject Category:Engineered_proteins.
- Aflibercept subject Category:Ophthalmology_drugs.
- Aflibercept type Abstraction100002137.
- Aflibercept type Chemical114806838.
- Aflibercept type Compound114818238.
- Aflibercept type EngineeredProteins.
- Aflibercept type Macromolecule114944888.
- Aflibercept type Material114580897.
- Aflibercept type Matter100020827.
- Aflibercept type Molecule114682133.
- Aflibercept type OrganicCompound114727670.
- Aflibercept type Part113809207.
- Aflibercept type PhysicalEntity100001930.
- Aflibercept type Protein114728724.
- Aflibercept type Relation100031921.
- Aflibercept type Substance100019613.
- Aflibercept type Thing100002452.
- Aflibercept type Unit109465459.
- Aflibercept type Drug.
- Aflibercept type DrugProduct.
- Aflibercept type Thing.
- Aflibercept type Q8386.
- Aflibercept comment "Aflibercept (INN, USAN) is a biopharmaceutical drug invented by Regeneron Pharmaceuticals, approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zaltrap.".
- Aflibercept label "Aflibercept".
- Aflibercept label "Aflibercept".
- Aflibercept label "Aflibercept".
- Aflibercept label "Aflibercept".
- Aflibercept sameAs Aflibercept.
- Aflibercept sameAs Aflibercept.
- Aflibercept sameAs アフリベルセプト.
- Aflibercept sameAs Aflibercept.
- Aflibercept sameAs m.04cx_t5.
- Aflibercept sameAs Q4689286.
- Aflibercept sameAs Q4689286.
- Aflibercept sameAs Aflibercept.
- Aflibercept wasDerivedFrom Aflibercept?oldid=626396821.
- Aflibercept isPrimaryTopicOf Aflibercept.